The aim of this work is to evaluate the safety and efficacy of combined use of topical platelet rich plasma (PRP) -PRP clot and eye drops- and amniotic membrane graft (AMG) in the management of corneal perforations and compare the results with AMG alone. Methods: This is an interventional comparative prospective randomized clinical study. Thirty-six eyes with infectious perforated central corneal ulcer. These eyes were classified into two groups each of 18 eyes. In group (A), eyes were treated by AMG combined with PRP clot to seal the central corneal perforation followed by PRP eye drops 6 times per day. In group (B), eyes were treated by AMG alone. Results: Most of the cases had anterior chamber formation within 24 hours; 94.4% and 66.7% in groups (A & B), respectively with statistically highly significant (P = .035), stability of the graft was better in group (A) without statistically significant difference (P = .03). Complete resolution of infectious perforated corneal ulcer was achieved in 18 eyes (100 %) and 14 (77.8%) in groups (A & B), respectively with statistically highly significant difference (P <0.001). Failure was not observed in any eyes (0 %) in group (A) and in 4 eyes (22.2%) in group (B) with statistically highly significant difference (P < .001). Conclusions: PRP clot and eye drops can be used as an available and effective adjuvant therapy to AMG for treating infectious central corneal perforation. This enhances the sealing of corneal perforation and anterior chamber (AC) reformation and fasten the healing of infectious perforated corneal ulcer with better visual improvement and less complications.